Blastic Plasmacytoid Dendritic Cell Neoplasm
📧 Sign up to get email alerts when something new happens for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-11-03FDA Approved: ELZONRIS — Supplemental Application (Stemline Therapeutics, Inc.)
FDA has approved a supplemental application for ELZONRIS (tagraxofusp) submitted by Stemline Therapeutics, Inc., reflecting an update to its…
-
FDA approval · 2022-10-27FDA Approved: ELZONRIS — Supplemental Application (Stemline Therapeutics, Inc.)
The FDA approved a supplemental application for ELZONRIS (tagraxofusp) from Stemline Therapeutics, Inc.
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes [Phase 1, Phase 2]
Clinical trial update for DT388IL3 fusion protein in acute myeloid leukemia and myelodysplastic syndromes (Phase 1/2) completed with results…
-
FDA approval · 2018-12-21FDA Approved: ELZONRIS — Original Application (Stemline Therapeutics, Inc.)
FDA approves ELZONRIS (tagraxofusp) from Stemline Therapeutics in the original application for blastic plasmacytoid dendritic cell neoplasm …
-
CLINICAL_TRIALS research · 2016-08-09Clinical Trial Update: Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)
This clinical trial update provides a descriptive assessment of the efficacy of treatments used for Blastic Plasmacytoid Dendritic Cell Neop…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.